<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111223</url>
  </required_header>
  <id_info>
    <org_study_id>STU00216104</org_study_id>
    <nct_id>NCT05111223</nct_id>
  </id_info>
  <brief_title>Testing the Contribution of Orbitofrontal Cortex Networks to Decision-making</brief_title>
  <official_title>Testing the Contribution of Orbitofrontal Cortex Networks to Decision-making</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study examines the contribution of orbitofrontal cortex (OFC) networks to&#xD;
      decision-making.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will combine functional magnetic resonance imaging (fMRI), non-invasive&#xD;
      transcranial magnetic stimulation (TMS), olfactory stimuli, and a devaluation task to define&#xD;
      the specific contributions of orbitofrontal cortex (OFC) networks in outcome-guided behavior.&#xD;
      We will use network-targeted TMS to modulate activity within anterior OFC and posterior OFC&#xD;
      networks, examining if they have different contributions to decision-making. This is a&#xD;
      randomized, between-subjects design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Behavior on devaluation task</measure>
    <time_frame>1 hour after intervention</time_frame>
    <description>Percentage of cues predicting non-devalued vs devalued odors chosen during the devaluation task.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resting-state functional magnetic resonance imaging</measure>
    <time_frame>1 hour after intervention</time_frame>
    <description>Resting-state activity determined by functional magnetic resonance imaging.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TMS targeting anterior OFC networks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TMS and sham targeting the anterior OFC network.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMS targeting posterior OFC networks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TMS and sham targeting the posterior OFC network.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Real transcranial magnetic stimulation (TMS) before conditioning</intervention_name>
    <description>Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.</description>
    <arm_group_label>TMS targeting anterior OFC networks</arm_group_label>
    <arm_group_label>TMS targeting posterior OFC networks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Real transcranial magnetic stimulation (TMS) before devaluation test</intervention_name>
    <description>Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.</description>
    <arm_group_label>TMS targeting anterior OFC networks</arm_group_label>
    <arm_group_label>TMS targeting posterior OFC networks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham transcranial magnetic stimulation (TMS)</intervention_name>
    <description>Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.</description>
    <arm_group_label>TMS targeting anterior OFC networks</arm_group_label>
    <arm_group_label>TMS targeting posterior OFC networks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 40 years old&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  Fluent English speakers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of significant neurological conditions (e.g., epilepsy, dementia, multiple&#xD;
             sclerosis, brain tumors, etc.)&#xD;
&#xD;
          -  History of major psychiatric conditions (e.g., general anxiety disorder, depression,&#xD;
             schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder,&#xD;
             attention deficit hyperactivity disorder, substance use disorder, etc.)&#xD;
&#xD;
          -  Significant medical illnesses (e.g., cancer, meningitis, chronic obstructive pulmonary&#xD;
             disease, cardiovascular disease, etc.)&#xD;
&#xD;
          -  Significant cerebrovascular risk factors (e.g., hypertension, diabetes, elevated&#xD;
             cholesterol, etc.)&#xD;
&#xD;
          -  Current use of psychoactive medications (e.g., barbiturates, benzodiazepines, chloral&#xD;
             hydrate, haloperidol, lithium, carbamazepine, phenytoin, citalopram, escitalopram,&#xD;
             fluoxetine, diazepam, etc.)&#xD;
&#xD;
          -  Smell or taste dysfunction&#xD;
&#xD;
          -  History of significant allergies requiring hospitalization for treatment&#xD;
&#xD;
          -  History of severe asthma requiring hospitalization for treatment&#xD;
&#xD;
          -  Habitual smoking&#xD;
&#xD;
          -  History of eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge-eating&#xD;
             disorder, etc.)&#xD;
&#xD;
          -  Dieting or fasting&#xD;
&#xD;
          -  Magnetic implants (e.g., shunts or stents, aneurysm clips, surgical clips, cochlear&#xD;
             implants, metal bone/joint pins, plates and screws, eyelid spring or wires, etc.)&#xD;
&#xD;
          -  Electronic devices (e.g., implanted cardiac defibrillator, cardiac pacemaker, deep&#xD;
             brain/spinal cord or nerve stimulator, internal electrodes/wires, medication infusion&#xD;
             devices, etc.)&#xD;
&#xD;
          -  History of metal working without proper eye protection, or injury with metal shrapnel&#xD;
             or metal slivers&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Predisposition to seizures (e.g., personal history of seizures, family history of&#xD;
             seizures epilepsy, pregnancy, alcoholism, etc.)&#xD;
&#xD;
          -  Use of medications that increase the likelihood of seizures (e.g., bupropion SR,&#xD;
             citalopram, duloxetine, ketamine, gamma-hydroxybutyrate, etc.)&#xD;
&#xD;
          -  History of surgical procedures performed on the brain or spinal cord&#xD;
&#xD;
          -  History of severe head trauma followed by loss of consciousness&#xD;
&#xD;
          -  History of fainting spells or syncope&#xD;
&#xD;
          -  Hearing problems or tinnitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thorsten Kahnt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daria Porter, PhD</last_name>
    <phone>774-280-0048</phone>
    <email>daria.porter@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thorsten Kahnt, PhD</last_name>
    <phone>312-503-2896</phone>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Thorsten Kahnt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data that underlie results in a publication</ipd_description>
    <ipd_time_frame>Upon publication</ipd_time_frame>
    <ipd_access_criteria>Data can be obtained from PI for non-profit purposes upon reasonable request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

